Eur Rev Med Pharmacol Sci 2022; 26 (1): 54-58

DOI: 10.26355/eurrev_202201_27747

Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy

L. Puccetti, V. Sammartano, P. Calzoni, F. Bacchiarri, A. Santoni, D. Fineschi, M. Bocchia

Hemostasis and Thrombosis Unit, “Santa Maria alle Scotte” University Teaching Hospital of Siena, University of Siena, Siena, Italy. luca.puccetti@unisi.it


OBJECTIVE: Direct-acting oral anticoagulants (DOACs) have established indications, according to recent guidelines for the treatment and prevention of venous thromboembolism (VTE), including pulmonary embolism (PE), with a safer profile compared to vitamin K antagonist (VKA) in terms of a lower risk for major bleeding and no need of blood coagulation tests. However, DOACs are not indicated in the treatment of patients with triple-positive antiphospholipid syndrome (APS). This limitation is often extended in clinical practice to patients with isolated positivity. The COVID-19 pandemic has sometimes made it difficult to maintain a safe VKA treatment, due to the practical difficulties of performing INR.

PATIENTS AND METHODS: We evaluated 39 patients with a previous unprovoked VTE/PE, who were no longer eligible for VKA treatment due to the difficulty of performing INR during the COVID-19 pandemic lockdown, in Italy. All patients had a positive LAC and refused a long-term anticoagulation with low molecular weight heparin. They were shifted to edoxaban.

RESULTS: Any recurrence of VTE/PE occurred during the observation period (up to eight months of treatment), while only one minor bleeding event was recorded (Hazard ratio=0.06, 95% confidence interval 0.03-0.11, p=0.094). No arterial events occurred during the observation period. Hemoglobin, platelets, and creatinine were unchanged during the observation period.

CONCLUSIONS: Edoxaban treatment may be safe and effective in preventing the recurrence of VTE/PE in patients with isolated LAC positivity, without the occurrence of arterial events.

Free PDF Download

To cite this article

L. Puccetti, V. Sammartano, P. Calzoni, F. Bacchiarri, A. Santoni, D. Fineschi, M. Bocchia
Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 1
Pages: 54-58
DOI: 10.26355/eurrev_202201_27747